Dong O, Manga N, Zhong Y, Zhang Y, Krause T, Griffin J, Herring WL, Wolowacz S. Use of patient-reported outcomes as key drivers in cost-effectiveness models: a review of UK National Institute for Health and Care Excellence health technology assessments. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S78. doi: 10.1016/j.jval.2023.03.405
Yucel E, Hartley L, Bell J, Wolowacz S, Kamgar F, Hawe E. A systematic literature review of utility estimates for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S395. doi: 10.1016/j.jval.2022.09.1964
Whalley D, Belongie K, Frangiosa T, Krasa H, Mladsi DM, Twiss J, Wolowacz S. Understanding the patient experience of erythropoietic protoporphyria and x-linked protoporphyria: a qualitative study. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Bego G, Tavi J, Wang Z, Kuznik A, Brignoli L, Mnif T, Wolowacz S, Jia X. Quality of life of caregivers of pediatric patients with atopic dermatitis: a quantitative assessment of utilities from EQ-5D. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2022 Jan; 25(1, Supplement):S101. doi: 10.1016/j.jval.2021.11.480
Jen MH, Sonksen M, Kiiskinen U, Wolowacz S, Vickers AD, Hawe E. Surrogate outcomes for overall survival in pretreated non-small cell lung cancer: expanding the prediction range. Poster presented at the Virtual ISPOR Europe 2021; December 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
Aronsson M, Dunton K, Hawe E, Wolowacz S, Quoraishi S, Durrington P, Ray KK, Bilitou A. Building a cost-effectiveness MODEL framework from a payer's perspective to assess NOVEL treatments in primary hypercholesterolaemia and MIXED dyslipidaemia: challenges in a world of LDL-C lowering. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Cawson M, Wolowacz S, Doward L, Sinha A. Health utility estimates for congenital cytomegalovirus disease: conceptual design considerations. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Zuluaga S, Hess LM, Wolowacz S, Dyachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for the treatment of locally advanced or metastatic soft tissue sarcoma in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A108.
Wolowacz S. New ISPOR recommendations - mapping methods for estimation of health state utility. Value Health. 2017 Jan;20(1):28-9. doi: 10.1016/j.jval.2016.11.026
Wolowacz S. Editorial: ISPOR good research practices task force report—mapping to estimate utility values from non–preference-based outcome measures. Value Health. 2017 Jan;20(1):28-9. doi: 10.1016/j.jval.2016.11.026
Bertwistle D, D'yachkova Y, Vickers AD, Hawe E, Fernandez M, Drove N, Lorenzo M, Wolowacz S. Comparative efficacy and saftey of interventions in the treatment of advanced soft tissue sarcoma: a systematic review and network meta analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A712.
Wolowacz S, ISPOR Task Force. Response to editorial: estimating health-state utility for economic models in clinical studies: An ISPOR good research practices task force report. Value Health. 2016 Sep;19(6):702-3. doi: 10.1016/j.jval.2016.08.728
Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, Lloyd A, Norman R. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016 Sep;19(2016):704-19. doi: 10.1016/j.jval.2016.06.001
Herring WL, Pearson IV, Purser MF, Nakhaipour HR, Haiderali A, Wolowacz SE, Jayasundara K. Cost-effectiveness of ofatumumab plus chlorambucil in first line chronic lymphocytic leukemia in Canada. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):PA633.
Wolowacz S, Brockbank J, Sunderland TJ, Gonschior AK. Cost-effectiveness of dabigatran etexilate for the secondary prevention of recurrent deep vein thrombosis and pulmonary embolism in the United Kingdom. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A526.
Helbert M, Pang F, Alvarez-Reyes M, Pearson IV, Wolowacz S, Diwakar L. A cost-effectiveness comparison of icatibant and c1-esterase inhibitor concentrate for the symptomatic treatment of acute attacks of types i and ii hereditary angioedema in the UK setting. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 13, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A513.
Pearson IV, Wolowacz SE, Irving AH, Brockbank JA, Chubb B, Gundgaard J, Briggs A, Davies M. A systematic review of recent data describing the risk of complications in type 1 diabetes mellitus patients. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A496-7.
Roskell N, Wolowacz S, Christiansen AV, Plumb JM. Are double-blind, double-dummy studies suitable for resource utilisation analyses? An example from a new oral anticoagulant for the prevention of venous thromboembolism (VTE) following orthopaedic surgery. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A167.
Wolowacz S, Samuel M, Brennan VK, Jasso-Mosqueda J, van Gelder I. The cost of illness of atrial fibrillation: a systematic review. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A325.
Zimovetz E, Wolowacz S. Reviewer's checklist for assessing the quality of decision models. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A395.
Gonzalez-Rojas N, Vieta A, Monreal M, Wolowacz SE. Economic analysis of dabigatran etexilate for the primary prevention of venous thromboembolism following total hip or knee replacement in Spain. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 24, 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A440.
Wolowacz S, Roskell N, Plumb J, Clemens A, Robinson P, Dolan G, Brenkel I. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. [abstract] Value Health. 2009 May; 12(3):A151.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150 MG for the prevention of venous thromboembolism in patients aged over 75 years undergoing total hip or knee arthroplasty. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 14, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty with moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 15, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Mateus C, Wolowacz S, Pereira JA. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in total hip and knee replacement in Portugal. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A148.
Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson P, Plumb J. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in patients undergoing total hip or total knee replacement surgery. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A404.
Brennan VK, Wolowacz SE. A systematic review of breast cancer utility weights. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A77.
Javitt JC, Wolowacz SE, Roskell NS, Maciver F, Kelly S, Pleil AM, Zlateva GP. Cost-effectiveness of pegaptanib in age-related macular degeneration: the impact of differences between USA and UK health care systems. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.
Wolowacz SE, Roskell NS, Maciver F, Kelly S. Cost-utility analysis for pegaptanib in age-related macular degeneration in the UK: the impact of demographic and disease characteristics. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.
Wolowacz SE, Roskell NS, Christie A, Kerr G, Cameron D. Per-patient cost of hospital care for advanced breast cancer in the UK based on a large patient-level resource utilisation dataset. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A42.